États-Unis · Plateformes & données · Stocktwits

MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing

Publié par Stocktwits · États-Unis il y a 9 h

Résumé détaillé

MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments.

Lire l'article complet sur Stocktwits Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stocktwits.com)

MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing

Résumé détaillé

À lire aussi

Automatic Data Processing, Inc. (NASDAQ:ADP) Plans Quarterly Dividend of $1.90

Your holiday credit-card bills are going up. What you can do to ease the pain.

Here are the major earnings before the open Thursday

AEVEX Q3 2026 slides: core business surges as Ukraine revenue fades

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing

Résumé détaillé

Partager

À lire aussi

Automatic Data Processing, Inc. (NASDAQ:ADP) Plans Quarterly Dividend of $1.90

Your holiday credit-card bills are going up. What you can do to ease the pain.

Here are the major earnings before the open Thursday

AEVEX Q3 2026 slides: core business surges as Ukraine revenue fades

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030